Kornimate/medical-research-clean huggingface dataset:
retrospective comparison between airseal® and standard insufflation in appendicular peritonitis

Conditions: Peritonitis; Acute; Acute Appendicitis; Postoperative Pain; Laparoscopy

Summary: the airseal system valve-less trocar is known to decrease postoperative pain, consumption of analgesics, operating time, and length of stay in adults during robotic and laparoscopic procedures. the investigators would like to know if these allegations also apply to children.

from january the 1st 2022 to december the 31st 2022, 100 children aged under 18 years old had an appendicular peritonitis treated by laparoscopic appendectomy. the pediatric surgeons either used the airseal system valve-less trocar or the standard insufflation. on one hand, only the surgeon, the anesthetist and the nurses of the operating room knew which type of insufflation was used. on the other hand, the patient, his parents and the nurses in the pediatric department did not know which type of insufflation was used. the participants were divided in two groups: the airseal group (a) and the standard group (s). in each group, the investigators studied and compared the postoperative pain, the consumption of analgesics, the operating time, and the length of stay for each participant.

Eligibility criteria:
inclusion criteria: * children aged between 4 and 17 years old * who underwent laparoscopic appendectomy for appendicular peritonitis * between 2022/06/1st and 2022/12/31st exclusion criteria: * children younger than 4 years old or older than 18 years old * who did not have appendicular peritonitis * between 2022/01/1st and 2022/12/31st

Keywords: valveless trocar low-pressure insufflation standard insufflation laparoscopic appendectomy appendicular peritonitis retrospective study
sleep disorders after tips

Conditions: Sleep Disorder

Summary: the purpose of a study to investigate the incidence of postoperative sleep disorders in patients undergoing transjugular intrahepatic portosystemic shunt ,and to analyze the relationship between risk factors and prognosis of sleep disorders.


Eligibility criteria:
inclusion criteria: 1. history of cirrhosis (clinical or by liver biopsy) 2. portal hypertension patients with defined indications for tips treatment 3. aged 18-75 years old 4. signed written informed consent exclusion criteria: 1. mental or nervous system diseases 2. patients with alcoholic cirrhosis who are still drinking 3. accompanied by serious heart, lung, brain and kidney diseases 4. preoperative diagnosis of sleep disorder 5. patients who are illiteracy 6. the total score of the preoperative hamilton anxiety scale was greater than or equal to 14 points, and the total score of 17 points of the hamilton depression scale was greater than or equal to 18 points
evaluation of an investigational blood glucose monitoring system

Conditions: Diabetes

Summary: the purpose of this study was to determine if untrained subjects who have diabetes can operate the investigational blood glucose monitoring system (bgms) and obtain valid glucose results.


Eligibility criteria:
inclusion criteria: 1. males and females, 18 years of age and older 2. people with type 1 or type 2 diabetes 3. able to speak, read, and understand english 4. willing to complete all study procedures exclusion criteria: 1. hemophilia or any other bleeding disorder 2. pregnancy 3. physical, visual, or neurological impairments that would make the person unable to perform testing with the bgm 4. previously participated in a bg monitor study using the ninja 3 bgms 5. working for a medical laboratory, hospital, or other clinical setting that involves training on and clinical use of blood glucose monitors 6. working for a competitive medical device company, or having an immediate family member who works for such a company 7. a condition which, in the opinion of the investigator or designee, would put the person or study conduct at risk. the enrollment criteria for the study population: 1. at least 60% of subjects will be younger than age 65 2. at least 20% of subjects will have type 1 diabetes 3. at least 50% of subjects with type 2 diabetes wil be insulin users.
disruption of memory reconsolidating as a treatment for panic disorder

Conditions: Panic Disorder

Summary: animal and human fear conditioning studies have repeatedly shown that administering propranolol before or after retrieval of a previously acquired fear results in an elimination of the fear expression. this approach, known as disruption of fear memory reconsolidation, is a promising new avenue for treating anxiety disorders. the present study aims to test its efficacy in patients with panic disorder.


Eligibility criteria:
inclusion criteria: * a primary diagnosis of panic disorder according to dsm-v * written approval of an independent physician for participation exclusion criteria: * other relevant treatment for panic disorder at the time of study - e.g., cognitive behavioral therapy (cbt) * diagnosis of depression * diagnosis of psychosis * use of psychotropic medication * history of pulmonary diseases * metabolic acidosis * history of cardiovascular diseases * heart problems among first-degree relatives * heart rate (hr) \< 60 * blood pressure (bp) \ 170-100 * history of black-outs or fainting * diabetes * liver or kidney diseases * hyperactive production of thyroid hormones * epilepsy * any medication contra-indicative of the use of propranolol * pregnancy
atg in haploidentical hsct for acute graft-versus-host disease prophylaxis

Conditions: Hematopoietic Stem Cell Transplantation; Antithymocyte Globulin; Viral Infection

Summary: the purpose of this study is to compare the incidences of gvhd and viral infections in haploidentical hematopoietic stem cell transplant recipients receiving different dose of antithymocyte globulin (atg) for acute graft-versus-host disease(agvhd) prophylaxis. our first objective was to investigate the optimal dose of atg for agvhd and second object was to evaluate the effect of different dose of atg on post-transplant viral infection.

allogeneic hematopoietic stem cell transplantation (allo-hsct)is the only therapeutic option for many hematological malignancies. unfortunately, about 75% of patients who require allo-hsct lack human leukocyte antigen (hla)-matched donors. the alternative is hematopoietic stem cells from an hla-mismatched family donor. however, this strategy, which is called haploidentical hsct, may be associated with high risk of early death and severe gvhd. opportunistic infections are common complications after allo-hsct. due to the absence of effective preventive and therapeutic drugs for most viruses, viral infections has become one of the most important causes of death. the immunosuppression regimen including atg has been shown effective to prevent severe gvhd in haploidentical hsct. but this strategy delays immune reconstitution, and therefore increase the risk of viral infection. the optimal dose of the different atg preparations with respect to prevention of gvhd is not fully understood today. the total doses between 6 mg/kg to 15 mg/kg are effective for prevention of gvhd, but the dose above 10 mg/kg may increase the development of viral infection. in this trial, we will focus on the incidence of agvhd and viral infections in patients treated with 7.5mg/kg or 10mg/kg of atg. the incidence of gvhd and viral infections will be compared between different dose arms.

Eligibility criteria:
inclusion criteria: * a patient age of 14-65 years * haploidentical hematopoietic stem cell transplant recipient * subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study exclusion criteria: * any abnormality in a vital sign (e.g., heart rate, respiratory rate, or blood pressure) * patients with any conditions not suitable for the trial (investigators' decision)

Keywords: haploidentical hematopoietic stem cell transplantation antithymocyte globulin viral infection
creation of auditory processing disorder screening tool in french

Conditions: Auditory Processing Disorder

Summary: the objective of the study is to validate a screening tool for auditory processing disorder in children of 7 to 13 years old. this screening tool was created based on literature and combines a questionnaire and a mini-battery of tests composed of verbal and nonverbal assessments.

hearing plays a vital role in the development of a child. hearing is based on two main systems: the peripheral system and the central system. peripheral hearing, which includes the outer, middle, and inner ear and the auditory nerve, can detect sound signals. for its part, the central system, which is composed of auditory structures from the auditory nerve to the brain, makes it possible to process these sound signals and to analyze them. peripheral hearing damage will result in deafness while a problem in the central auditory system will be called auditory processing disorder. peripheral deafness can be detected from birth through neonatal screening for deafness. the symptoms of an auditory processing disorder can easily be confused with those caused by attention deficit disorder with or without hyperactivity and a specific language disorder. auditory processing disorder is often unknown in the medical and educational worlds, and children are referred late for consultation. in addition, the lack of french screening tests for auditory processing disorder and the long waiting lists for specialized consultations help to delay diagnosis and hinder early intervention. auditory processing disorder affects about 2 to 3% of school-aged children. the objective of the study is to validate a screening tool for auditory processing disorder in children of 7 to 13 years old. this screening tool was created based on literature and combines a questionnaire and a mini-battery of tests composed of verbal and nonverbal assessments.

Eligibility criteria:
inclusion criteria: * child aged 7 to 13 on the day of enrollment. * child referred for assessment of central auditory skills, who did not have an auditory processing disorder -type assessment before. * hearing thresholds at both ears between 0 decibels hearing level (db hl) and 15 db hl at 250, 500, 1000, 2000, 4000 and 8000 hz. absence of auditory neuropathy. * child affiliated to a social security scheme. * holders of parental authority who do not oppose the patient's participation in research. exclusion criteria: * known neurological disorder (epilepsy, cranial trauma, etc.). * non medicated attention deficit since the presence of such a deficit can affect the child's performance during the auditory processing disorder assessment. * intellectual disability since impairment of cognitive skills may also explain poor test performance (iq \<80).

Keywords: auditory processing disorder screening tool children
evaluation of the german version of a validated keratoconus questionaire

Conditions: Keratoconus, Unspecified, Bilateral

Summary: keratoconus, which results in thinning of the cornea, affects mainly young patients. the causes are currently only partially known. the aim of this study is the evaluation of a keratoconus questionnaire in german. until now this questionnaire is only in use in english. within the study patients will be asked to fill out a questionnaire. the questionnaire deals with issues that are influenced by keratoconus: visual impairment and its impact on quality of life. this questionnaire (korq) is an already validated questionnaire in english. within this study we would like to translate the questionnaire and validate it in german. within this study 50 patients will be included for the validation of the questionnaire. based on previous studies evaluating the keratoconus questionnaire (korq) in other languages, a number of 50 patients has been shown to be sufficient for validation. no control examination is necessary for this study.


Eligibility criteria:
inclusion criteria: * keratoconus * signing of a written consent form for participation in the study exclusion criteria: * difficulty in understanding patient information
influence of vitamin c on post-operative atrial fibrillation

Conditions: Atrial Fibrillation

Summary: post-operative atrial fibrillation (poaf) is the most common arrhythmia which typically develops 2-3 days after cardiac surgery. the incidence of poaf variates between 10% and 65% depending on the type of cardiac surgery and is especially high in patients which underwent coronary artery bypass grafting (cabg) and heart valve surgery. poaf is associated with increased morbidity and mortality and has a major impact on hospital resources. the precise pathogenesis of poaf is very complex, but several studies have demonstrated an association between inflammation, oxidative stress and poaf. since this oxidative stress may be reduced by dietary anti-oxidantia such as vitamin c, the aim of this study is to evaluate the effect of oral vitamin c administration of the incidence of poaf.

after obtaining informed consent, patients which are planned for cabg or heart valve surgery are randomly assigned into the vitamin c group or placebo group. each patient will receive 1 g vitamin c or placebo twice a day from 5 days before until 10 days after surgery. the medication will be given orally and both patient and surgeon are blinded for the administrated medication. patients receive standard of care in the post-operative period, which includes close monitoring for possible arrhythmias. if such an arrhythmia develops, this is treated according to the normal procedures. all information such as the used medication, the hospitalization / icu length of stay and the ventilation time is automatically registered in the patient records. from each patient, three additional blood samples (peri-operative, post-operative day 0, post-operative day 1) will be obtained for analysis of neutrophil gelatinase-associated lipocalin (ngal), a possible marker of subclinical kidney damage. these samples will be analysed in batch once all samples are collected.

Eligibility criteria:
inclusion criteria: * signed informed consent * eligible for elective cardiac surgery * preoperative sinus rhythm exclusion criteria: * patients who do not want to participate

Keywords: post-operative atrial fibrillation ascorbic acid vitamin c antioxidant cardiac surgery
brexpiprazole in patients with acute schizophrenia

Conditions: Schizophrenia

Summary: to determine the efficacy and safety of brexpiprazole for the treatment of adults experiencing an acute episode of schizophrenia.


Eligibility criteria:
inclusion criteria: * the patient has schizophrenia, diagnosed according to dsm-iv-tr™ and confirmed by the mini international neuropsychiatric interview (mini). * the patient has an acute exacerbation of psychotic symptoms and marked deterioration of usual function. * the patient is willing to be hospitalised from the screening visit through week 6. * the patient will benefit from hospitalisation or continued hospitalisation for treatment of a current acute relapse of schizophrenia at study entry. * the patient has a history of relapse and/or exacerbation of symptoms when not receiving antipsychotic treatment, excluding the current episode. * the patient agrees to protocol-defined use of effective contraception. exclusion criteria: * the patient has a current axis i diagnosis (dsm-iv-tr™ criteria) other than schizophrenia established as primary diagnosis. * the patient suffers from a current axis ii diagnosis (dsm-iv-tr™ criteria). * the patient suffers from mental retardation, organic mental disorders, or mental disorders due to a general medical condition (dsm-iv-tr™ criteria). * the patient, in the opinion of the investigator or according to columbia suicide severity rating scale (c-ssrs), is at significant risk of suicide. * the patient has clinically significant tardive dyskinesia or severe akathisia at enrolment. * the patient has a history of neuroleptic malignant syndrome. * the patient has any relevant medical history or current presence of systemic disease. * the patient has, at the screening visit an abnormal ecg or other abnormal ecg tests that are, in the investigator's opinion, clinically significant. * the patient has a history of cancer, other than basal cell or stage 1 squamous cell carcinoma of the skin, that has not been in remission for \>5 years prior to the first dose of brexpiprazole. * the patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason. other inclusion and exclusion criteria may apply.
peak systolic global longitudinal strain and low cardiac output syndrome after cardiac surgery

Conditions: Low Cardiac Output Syndrome After Adult Cardiac Surgery

Summary: this is a retrospective observational study to assess the relationship between peak systolic global longitudinal strain measured on pre-cardiopulmonary bypass trans-esophageal echo images predicts post-operative low cardiac output syndrome defined as the need for an inotropic support during 24 hours or longer.


Eligibility criteria:
inclusion criteria: * cardiac surgery involving the use of cardiopulmonary bypass * availability of pre-cardiopulmonary bypass trans-oesophageal echo images allowing measurement of the peak systolic global longitudinal strain exclusion criteria: * preoperative atrial fibrillation * preoperative critical state * emergent/salvage surgery * heart transplant surgery * left ventricular assist device implantation
observation on the correlation between serum/fecal isoflavones, abundance of tma-producing bacteria and serum tmao in hyperlipidemia and healthy subjects

Conditions: Hyperlipidemia

Summary: previous studies have shown that trimethylamine n-oxide (tmao), a gut microbiota-related metabolite, plays a significant role in the development and progression of cardiovascular disease (cvd). how to regulate the structure of gut microbiota to reduce circulating tmao levels in the host is currently one of the hot topics in research. diet is a major factor shaping the structure of gut microbiota. through the exploration of dietary elements, we have found that multiple epidemiological studies suggest an inverse correlation between the intake of isoflavones and cvd, indicating that isoflavones are potential agents for the prevention and treatment of cvd. interestingly, isoflavones have poor water solubility and low bioavailability. several studies have confirmed interactions between isoflavones and gut microbiota, suggesting that the gut and gut microbiota are likely important therapeutic targets for isoflavones in preventing and treating cvd. furthermore, a high-fat diet (hfd) is also an independent risk factor for cvd. research literature indicates that hfd can disrupt both the gut and gut microbiota. as a biomarker for cvd risk, tmao has been reported in some studies to increase in circulation following hfd intake, but the mechanisms behind this phenomenon require further exploration. based on the above literature, we propose a scientific hypothesis: can isoflavones regulate gut microbiota and subsequently reduce serum tmao levels in hfd-fed mice? this hypothesis can be further divided into three specific scientific questions: which isoflavones can reduce serum tmao levels in hfd-fed mice? is gut microbiota the key factor through which isoflavones reduce serum tmao levels in hfd-fed mice? what mechanisms do these substances use to modulate gut microbiota?


Eligibility criteria:
* inclusion criteria: * hyperlipidemia inclusion criteria: * 18-70 years old； * patients diagnosed with hyperlipidemia； * healthy people inclusion criteria: * 18-70 years old； * male weight ≥50.0kg, female weight ≥45.0kg; body mass index (bmi) within the range of 19.0-26.0 kg/m2 (including critical values); * volunteers have no history of chronic diseases or serious diseases such as cardiovascular, liver, kidney, respiratory, blood and lymphatic, endocrine, immune, mental, neuromuscular, gastrointestinal system within three years, and are in good overall health. * exclusion criteria: * consuming dietary supplements (ω-3 fatty acids, probiotics, prebiotics, plant stanols/sterols) 1 month before the study; * using antibiotics, antidiarrheal drugs, statins, fibrates and other drugs within 2 months before the study; * drinking alcohol (\> 2 cups per day); * hyperlipidemia patients with inflammatory bowel disease or irritable bowel syndrome and healthy people.

Keywords: hyperlipidemia tmao gut microbes isoflavone
study to determine the pharmacokinetics of sulfasalazine in children with juvenile idiopathic arthritis

Conditions: Arthritis, Juvenile Rheumatoid

Summary: this study will characterize the steady state pharmacokinetics of sulfasalazine delayed release tablets in pediatric juvenile idiopathic arthritis patients. data from this study will fulfill the post approval commitment to the fda.


Eligibility criteria:
inclusion criteria: * patients with a diagnosis of oligoarticular, polyarticular, psoriatic or enthesitis-related jia as determined by ilar criteria. patients who have been continuously treated with generic sulfasalazine delayed release formulation and have tolerated the product for at least 3 months prior to study enrolment and who are switched to azulfidine-en at least 8 days prior to day 0 are eligible. * patients must be at least 6 years of age and has not reached his/her 18th birthday prior to the baseline visit (day 0). * onset of jia must have occurred prior to the patient's 16th birthday. * patients must weigh at least 20 kg. * patients must be on sulfasalazine 500 mg delayed release tablets and the total daily dose must be within the specified range of 30-60 mg/kg/day with a maximum daily dose of 3 g/day exclusion criteria: * patient currently with systemic features of systemic jia. * hypersensitivity to sulfasalazine , its metabolites, sulfonamides or salicylates. * history of sensitivity to heparin or heparin-induced thrombocytopenia. * inability to swallow whole (uncrushed) sulfasalazine 500 mg delayed release tablets as required by protocol

Keywords: sulfasalazine delayed release tablets azulfidine entabs pharmacokinetics juvenile idiopathic arthritis (jia)
dynamics of stroke volume and cardiac output during parabolic flight, and its relationship to intravascular volume

Conditions: Healthy Volunteers

Summary: to understand the cardiovascular reactions of the human body to changing conditions of gravity is an important aim of space science. in this context, cardiac output (co) is a key value to estimate the human cardiovascular system. the main objective of this experiment is to determine the effects of parabolic flight on intravascular volume, and how these changes modulate the complex haemodynamics induced by the parabolas.


Eligibility criteria:
inclusion criteria: * healthy volunteers (men or women), * aged from 18 to 55, * affiliated to a social security system, * who accept to take part in the study, * who have given their written stated consent, * who already participated in parabolic flights (even in the same campaign) * all subjects will pass a medical examination similar to a standard aviation medical examination for private pilot aptitude. there will be no additional test performed for subject selection exclusion criteria: * person who took part in a previous biomedical research protocol, of which exclusion period is not terminated, * pregnant women